V8 Peptides — Engineered Performance
Research Library
PT-141 and the Melanocortin Receptors: Assay Guide
PT-141Mechanism

PT-141 and the Melanocortin Receptors: Assay Guide

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

How does PT-141 fit into melanocortin receptor research? PT-141 (bremelanotide) is a cyclic melanocortin-receptor agonist that V8 lists as an MC4R research tool. The melanocortin system comprises five G-protein-coupled receptors, MC1R to MC5R, first cloned in 1992, which respond to alpha-MSH and ACTH peptides. Because the receptors are expressed in different tissues and the pharmacophore is shared, a study using PT-141 needs a selectivity panel across all five, defined reference agonists and antagonists, and a quantified signaling readout such as cAMP. This guide sets out that design, with citations to the receptor and structure-activity literature. Supplied for laboratory research use only.

The V8 PT-141 page describes the compound as a melanocortin MC4-receptor agonist (bremelanotide) studied for central melanocortin signaling in research models, with research areas in MC4R receptor research, central melanocortin signaling and neuroendocrine models. A well-designed experiment with any melanocortin ligand starts from the receptor family and not from the single receptor in the product description. This guide is the receptor-pharmacology side of the topic: the five receptors, what is known about their ligands, how selectivity is profiled, and how to avoid common interpretive errors. The molecule's chemistry is covered in the companion article on PT-141 structure, the lineage in the Melanotan II comparison, and the library entry is the PT-141 research overview. For laboratory research use only; nothing here concerns use in people.

The five receptors

The melanocortin receptors were identified by cloning. A 1992 study cloned murine and human MSH receptors and a human ACTH receptor and described them as a subfamily of G-protein-coupled receptors (Mountjoy et al., 1992). The later recognition of three additional receptors, MC3R, MC4R and MC5R, is described in the structure-activity literature: the MC2 receptor recognizes primarily ACTH peptides, whereas the other four receptors all recognize alpha-MSH and potent alpha-MSH agonists, and MC3R and MC4R are expressed in the brain while MC5R is expressed in a number of peripheral tissues (Hruby et al., 1995). Reviews of the system describe its physiological functions (Cone, 2006; Gantz and Fong, 2003).

ReceptorPrincipal endogenous ligands (per the cited literature)Expression noted in the cited literatureRelevance to a PT-141 panel
MC1Ralpha-MSHMelanocytes (pigmentation system)Off-target check; pigmentation readouts in melanoma cells
MC2RACTH peptides onlyAdrenal cortexExpected non-responder for alpha-MSH-type agonists
MC3Ralpha-MSH and agonistsBrainClosest neural paralog; key selectivity comparison
MC4Ralpha-MSH and agonistsBrainPrimary target named on the product page
MC5Ralpha-MSH and agonistsPeripheral tissuesOff-target check

For a reader new to the family, the practical message is that "an MC4R agonist" is shorthand. Potency at the other receptors is a measured quantity that has to be reported alongside MC4R values.

Why a selectivity panel is not optional

Melanocortin peptides share a core, His-Phe-Arg-Trp, and a ligand that fits one receptor tends to fit others to some degree. The structure-activity work makes the point directly: a study of cyclic lactam analogs reported that substituting bulky aromatic residues at position 7 gave high antagonist potency and selectivity at specific melanocortin receptors (Hruby et al., 1995), which shows that selectivity is tunable by small changes and, equally, that it can be lost by them. A sequence-level reading of PT-141 is in the companion structure article. For assay design the consequence is that an apparent MC4R effect in a tissue or whole-cell system should be supported by (a) a panel of cells each expressing one receptor, (b) a selective antagonist where available, and (c) a receptor-negative parental cell line.

Assay formats

The melanocortin receptors couple to Gs and raise intracellular cAMP, a coupling reported in the early adenylate-cyclase work on melanotropins (Sawyer et al., 1980, who measured activation of mouse melanoma adenylate cyclase for an alpha-MSH analog). Most modern panels read cAMP in cells expressing a single receptor, with binding assays as an orthogonal measure.

FormatReadsStrengthCaution
Radioligand or fluorescent-ligand bindingAffinity (Ki) by displacementDirect measure of occupancyDoes not report efficacy; needs a labeled ligand
cAMP accumulationGs signaling, EC50 and maximal responseFunctional; high throughputReceptor reserve in overexpressing cells inflates apparent potency
Reporter-gene (CRE) assayDownstream transcriptionSensitiveSlower; integrates other pathways
Pigment-cell bioassayMC1R-driven pigmentationClassic readout in frog-skin and melanoma systems (Sawyer et al., 1980)Reports only the MC1R axis
Native-tissue or primary-neuron assayMixed receptor populationCloser to physiologyCannot attribute a response to one receptor without antagonists

Controls and reference compounds

  • Endogenous reference agonist. alpha-MSH itself, as the benchmark for efficacy, since the receptors were defined by their response to it (Mountjoy et al., 1992).
  • Stable superpotent reference. The [Nle4, D-Phe7] analog of alpha-MSH, reported to resist degradation by serum enzymes and to have dramatically higher activity in classic assays (Sawyer et al., 1980), is useful where serum-containing medium is used and a labile peptide would degrade.
  • Selective antagonist. To attribute a response to MC4R, a blocker that discriminates it from MC3R, where available, is required; the position-7 lactam series described by Hruby and colleagues (1995) was developed for this purpose.
  • Parental cells. The same cell line without the receptor, to catch receptor-independent cAMP changes.
  • Vehicle matched to the diluent. Including any acid or buffer used to reconstitute the peptide.
  • Forskolin control. A direct adenylate cyclase activator, to confirm the cells can produce a cAMP signal when the receptor is bypassed.

Peptide handling issues that look like pharmacology

Several artifacts originate in the vial. Adsorption of a peptide to plastic can lower the effective concentration, especially in dilute solutions, and the choice of plasticware has been shown to matter in peptide studies (Goebel-Stengel et al., 2011). A stock that has partly oxidized, ring-opened or epimerized will show lower or altered potency, and the isobaric nature of D- and L-phenylalanine means mass spectrometry alone cannot exclude epimerization. Verification steps are in PT-141 purity testing and how to read a COA. Reconstitute per how to reconstitute a lyophilized peptide, prepare molar stocks from the formula C50H68N14O10 (average molar mass about 1,025.2 g/mol; the calculator converts mass and volume) and record the lot. Storage on the product page is refrigeration at 2–8 °C, −20 °C for long-term, protected from heat, moisture and light.

Worked example of an experimental layout

A minimal receptor-selectivity experiment can be laid out on paper before any cells are thawed. Prepare five stable cell lines, each expressing one of MC1R to MC5R, plus the parental line. Seed all six on one plate format so that the cell number per well is identical. Prepare a molar stock of the test peptide from its formula weight and make a half-log dilution series of at least eight concentrations, spanning several orders of magnitude, in the same diluent for every plate. Run alpha-MSH as the reference curve on every plate, include forskolin as a maximal-signal control and a vehicle-only column, and use triplicate wells for each point. Fit each curve with a four-parameter logistic model, report the EC50 with a confidence interval and the top of the curve as a percentage of the alpha-MSH maximum, and repeat on at least three independent days. A ratio of EC50 values between receptors is then a selectivity statement tied to that platform. If the MC4R curve of the test peptide is shifted rightward by a selective antagonist and the MC3R curve is not, that supports a receptor-specific attribution; if both shift, the antagonist is not discriminating at the concentration used.

Three failure modes recur. A flat curve in the parental line that rises with the peptide indicates receptor-independent cAMP generation. A curve whose top is far below the reference may be a partial agonist or a degraded stock. A curve that shifts between days with no change in method points to adsorption or storage of the stock, which is why aliquots of one stock should be used across a series.

Reporting results the way a pharmacologist reads them

A results table for a melanocortin ligand should show, for each receptor, the assay format, the cell system, n, the potency (EC50 or Ki) with confidence intervals, and the maximal response expressed relative to alpha-MSH. A statement of selectivity should be a ratio of potencies from the same assay platform, not a comparison of numbers across papers, since receptor expression level and assay format shift potency. Where a claim concerns a brain pathway, state that the receptor data are from recombinant cells or native tissue, and keep the cell-system conclusion separate from any claim about an animal model. Further reading in the library: KPV vs alpha-MSH covers a related melanocortin peptide, and the full catalog is in the shop; certificates are in the COA library.

Limits

This guide draws on abstracts and titles of receptor-cloning and structure-activity papers and on the product page. It does not report receptor potencies for PT-141, because the sources reviewed do not give them in their abstracts, and it makes no claim about biological effects in animals or people. Anyone who needs numerical potencies should read the primary pharmacology papers and, ideally, generate their own values on a defined panel with the controls above.

Frequently asked questions

How many melanocortin receptors are there?

Five, MC1R to MC5R. The first MSH and ACTH receptors were cloned in 1992, and MC3R to MC5R were identified afterward.

Which receptor does the V8 page name for PT-141?

The MC4 receptor. The page lists research areas in MC4R receptor research, central melanocortin signaling and neuroendocrine models.

Does MC2R respond to alpha-MSH?

The literature describes MC2R as recognizing primarily ACTH peptides, whereas the other four receptors recognize alpha-MSH and potent agonists.

Why run a panel across all five receptors?

Melanocortin ligands share a core pharmacophore, so activity at several receptors is common. Selectivity must be measured, not assumed.

What signaling readout is used?

Typically cAMP accumulation in cells expressing a single receptor, since these receptors couple to Gs, with binding assays as an orthogonal measure.

What controls does a melanocortin assay need?

A reference agonist (alpha-MSH), a stable analog where serum is present, a selective antagonist, parental cells, a vehicle control and a forskolin control.

Can overexpressing cells mislead potency?

Yes. Receptor reserve in overexpressing cells can inflate apparent potency, so comparisons should be made on the same platform.

Why does peptide handling matter in a pharmacology assay?

Adsorption, oxidation and ring-opening change the effective concentration and activity, and can mimic a pharmacological difference.

Does this article report PT-141 potencies?

No. The abstracts reviewed do not give them; the article describes how to measure them.

How should PT-141 be stored?

Per the product page: refrigerate at 2–8 °C, −20 °C for long-term, and protect from heat, moisture and light.

Research-use statement

All material discussed here is supplied for laboratory research use only; not for human consumption, and not a drug, food or cosmetic.

Related reading: PT-141 Structure: Cyclic Lactam, Sequence and Mass, How PT-141 Activates Melanocortin Receptors, Buying PT-141 for Research: What to Evaluate.

References

  1. Mountjoy KG, Robbins LS, Mortrud MT, Cone RD. The Cloning of a Family of Genes That Encode the Melanocortin Receptors. Science. 1992;257(5074):1248-1251. doi:10.1126/science.1325670
  2. Hruby VJ, Lu D, Sharma SD, de L. Castrucci A, Kesterson RA, Al-Obeidi FA, et al. Cyclic lactam .alpha.-melanotropin analogs of Ac-Nle4-cyclo[Asp5,D-Phe7,Lys10]-.alpha.-melanocyte-stimulating hormone-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. J. Med. Chem.. 1995;38(18):3454-3461. doi:10.1021/jm00018a005
  3. Cone RD. Studies on the Physiological Functions of the Melanocortin System. Endocrine Reviews. 2006;27(7):736-749. doi:10.1210/er.2006-0034
  4. Gantz I, Fong TM. The melanocortin system. American Journal of Physiology-Endocrinology and Metabolism. 2003;284(3):E468-E474. doi:10.1152/ajpendo.00434.2002
  5. Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, et al. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc. Natl. Acad. Sci. U.S.A.. 1980;77(10):5754-5758. doi:10.1073/pnas.77.10.5754
  6. Goebel-Stengel M, Stengel A, Taché Y, Reeve JR. The importance of using the optimal plasticware and glassware in studies involving peptides. Analytical Biochemistry. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.